AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 293 min read$FTRE

Fortrea (FTRE) Q3 2026 Earnings Call Transcript

Fortrea (FTRE) reported Q3 2026 revenue of $691.5M, adjusted EBITDA of $58M, and a book-to-bill ratio of 1.12x. The company raised full-year guidance and completed an acquisition to expand its clinical pharmacology capacity. Fortrea's strategy focuses on revenue growth and margin expansion through commercial, operational, and financial excellence.

Original reporting
finance.yahoo.com
Published Oct 29, 2026, 5:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 5:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Fortrea (FTRE) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$FTREBullishHigh
01

Why it matters

The earnings beat and raised guidance provide a fresh catalyst for price movement.

02

Market read

New earnings data and guidance raise are likely to drive short‑term trading activity in FTRE.

03

What to watch

Integration risk of the Early Phase Services acquisition could temper upside.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Fortrea reported Q3 2026 results, highlighted revenue growth, EBITDA improvement, and a strategic acquisition.

Company-level read

Ticker impact

$FTREBullishHigh confidence
Context

Q3 2026 earnings call disclosed revenue of $691.5M, adjusted EBITDA of $58M and raised full-year guidance.

Expected impact

likely upward pressure as market prices in higher revenue and EBITDA outlook

Evidence & confidence

New earnings numbers and guidance lift are fresh material that can move the stock immediately.

Market effects

Sector

Strengthens outlook for clinical research services sector.

Regional

Positive for U.S. and U.K. biotech service providers.

Global

Reinforces demand for early‑phase clinical trial capacity worldwide.

Counterpoint

What could challenge this read

If guidance raise is already priced in, the stock may face short‑term profit taking.

Key entities

  • company
    Fortrea

    Clinical research services provider.

Read at source← All news

StoryFortrea posts Q3 2026 results, raises full‑year guidance but EPS miss triggers stock slide

Also covered by

4 outlets

Related articles

OCT 30
$FTREMed

Truist raises Fortrea stock price target to $29 on margin outlook

Truist Securities raised its price target on Fortrea (NASDAQ:FTRE) to $29 from $26, maintaining a Buy rating. The stock trades at $23.14 with a $2.23B market cap. Fortrea reported a TTM book-to-bill ratio of 1.12x, below expectations, and expects Q4 adjusted EBITDA of $50M with a 7.5% margin, down from Q3. The company cited fewer working days and investments for the decline, but noted six consecutive quarters of margin upside and improving biotech demand.

investing.com2 min
OCT 30
$FTREMed

Fortrea Holdings Inc (FTRE) (Q3 2026) Earnings Call Highlights: Backlog Cleanup

Fortrea Holdings (FTRE) reported a $558M backlog adjustment, not impacting near-term revenue. Q4 EBITDA guidance was lowered due to fewer working days and IT investment. Gross margins improved from portfolio mix and efficiencies. CEO Anshul Thakral and CFO Jason Knobloch discussed growth strategies, including acquisitions like Worldwide Clinical Trials, and market recovery trends in biotech and biopharma. The company aims for mid-teens EBITDA margins and sees increasing RFP activity.

finance.yahoo.com2 min
OCT 29
$FTREHighAI 8/10

What Fortrea (FTRE) Said on Its Q3 Earnings Call

Fortrea (FTRE) reported Q3 net income of $0.6M, up from a loss of $15.9M YoY. Adjusted net income was $27.9M, and adjusted EPS was $0.28. Operating cash flow improved to $60.8M. The company acquired Early Phase Services, expanding its clinical pharmacology network. Fortrea raised its 2026 revenue guidance to $2.665B-$2.690B and adjusted EBITDA to $210M-$218M. Management expects biotech and biopharma demand recovery.

finance.yahoo.com2 min
OCT 29
$FTREHighAI 8/10

Fortrea Q3 2026 slides: EBITDA rises 14% as revenue falls short

Fortrea Holdings (FTRE) reported Q3 2026 revenue of $691.5M, down 1.4% YoY, missing estimates by $200.83M. Adjusted EBITDA rose 14.4% to $58.0M, with margins expanding to 8.4%. EPS missed by 55.6%, and the stock fell 11% premarket. Management raised full-year guidance but warned of Q4 revenue decline. The company acquired Worldwide Clinical Trials’ Early Phase Services for $45M, improving cash flow and liquidity.

investing.com3 min
OCT 29
$FTREHighAI 8/10

Fortrea (NASDAQ:FTRE) surprises with strong Q3 2026

Fortrea reported Q3 2026 revenue of $691.5 million, beating estimates by 3.1%, with adjusted EPS of $0.28, a 28.9% beat. Adjusted EBITDA was $58 million, an 7.7% beat. The company raised its full-year revenue guidance to $2.68 billion but lowered EBITDA guidance to $214 million. Operating margin improved to 2.2%, while free cash flow margin declined to 7.6%.

finance.yahoo.com2 min